Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 88

1.

Cross-sectional study into age-related pathology of mouse models for limb girdle muscular dystrophy types 2D and 2F.

Verhaart IEC, Putker K, van de Vijver D, Tanganyika-de Winter CL, Pasteuning-Vuhman S, Plomp JJ, Aartsma-Rus AM, van Putten M.

PLoS One. 2019 Aug 20;14(8):e0220665. doi: 10.1371/journal.pone.0220665. eCollection 2019.

2.

Natural disease history of the D2-mdx mouse model for Duchenne muscular dystrophy.

van Putten M, Putker K, Overzier M, Adamzek WA, Pasteuning-Vuhman S, Plomp JJ, Aartsma-Rus A.

FASEB J. 2019 Jul;33(7):8110-8124. doi: 10.1096/fj.201802488R. Epub 2019 Apr 1.

3.

MuSK myasthenia gravis monoclonal antibodies: Valency dictates pathogenicity.

Huijbers MG, Vergoossen DL, Fillié-Grijpma YE, van Es IE, Koning MT, Slot LM, Veelken H, Plomp JJ, van der Maarel SM, Verschuuren JJ.

Neurol Neuroimmunol Neuroinflamm. 2019 Feb 21;6(3):e547. doi: 10.1212/NXI.0000000000000547. eCollection 2019 May.

4.

Efgartigimod improves muscle weakness in a mouse model for muscle-specific kinase myasthenia gravis.

Huijbers MG, Plomp JJ, van Es IE, Fillié-Grijpma YE, Kamar-Al Majidi S, Ulrichts P, de Haard H, Hofman E, van der Maarel SM, Verschuuren JJ.

Exp Neurol. 2019 Jul;317:133-143. doi: 10.1016/j.expneurol.2019.03.001. Epub 2019 Mar 6.

5.

An automated hybrid bioelectronic system for autogenous restoration of sinus rhythm in atrial fibrillation.

Nyns ECA, Poelma RH, Volkers L, Plomp JJ, Bart CI, Kip AM, van Brakel TJ, Zeppenfeld K, Schalij MJ, Zhang GQ, de Vries AAF, Pijnappels DA.

Sci Transl Med. 2019 Feb 27;11(481). pii: eaau6447. doi: 10.1126/scitranslmed.aau6447.

PMID:
30814339
6.

Natural disease history of the dy2J mouse model of laminin α2 (merosin)-deficient congenital muscular dystrophy.

Pasteuning-Vuhman S, Putker K, Tanganyika-de Winter CL, Boertje-van der Meulen JW, van Vliet L, Overzier M, Plomp JJ, Aartsma-Rus A, van Putten M.

PLoS One. 2018 May 15;13(5):e0197388. doi: 10.1371/journal.pone.0197388. eCollection 2018.

7.

Low dystrophin levels are insufficient to normalize the neuromuscular synaptic abnormalities of mdx mice.

van der Pijl EM, van Putten M, Niks EH, Verschuuren JJGM, Aartsma-Rus A, Plomp JJ.

Neuromuscul Disord. 2018 May;28(5):427-442. doi: 10.1016/j.nmd.2018.02.013. Epub 2018 Mar 6.

8.

IgG4-mediated autoimmune diseases: a niche of antibody-mediated disorders.

Huijbers MG, Plomp JJ, van der Maarel SM, Verschuuren JJ.

Ann N Y Acad Sci. 2018 Feb;1413(1):92-103. doi: 10.1111/nyas.13561. Epub 2018 Jan 28. Review.

9.

Passive transfer models of myasthenia gravis with muscle-specific kinase antibodies.

Verschuuren JJGM, Plomp JJ, Burden SJ, Zhang W, Fillié-Grijpma YE, Stienstra-van Es IE, Niks EH, Losen M, van der Maarel SM, Huijbers MG.

Ann N Y Acad Sci. 2018 Feb;1413(1):111-118. doi: 10.1111/nyas.13543. Epub 2018 Jan 21. Review.

PMID:
29356029
10.

Neuromuscular synapse electrophysiology in myasthenia gravis animal models.

Plomp JJ, Huijbers MGM, Verschuuren JJGM.

Ann N Y Acad Sci. 2018 Jan;1412(1):146-153. doi: 10.1111/nyas.13507. Epub 2017 Oct 25. Review.

PMID:
29068559
11.

Acute and chronic effects of treatment with mesenchymal stromal cells on LPS-induced pulmonary inflammation, emphysema and atherosclerosis development.

Khedoe PPSJ, de Kleijn S, van Oeveren-Rietdijk AM, Plomp JJ, de Boer HC, van Pel M, Rensen PCN, Berbée JFP, Hiemstra PS.

PLoS One. 2017 Sep 14;12(9):e0183741. doi: 10.1371/journal.pone.0183741. eCollection 2017.

12.

Natural disease history of mouse models for limb girdle muscular dystrophy types 2D and 2F.

Pasteuning-Vuhman S, Putker K, Tanganyika-de Winter CL, Boertje-van der Meulen JW, van Vliet L, Overzier M, Plomp JJ, Aartsma-Rus A, van Putten M.

PLoS One. 2017 Aug 10;12(8):e0182704. doi: 10.1371/journal.pone.0182704. eCollection 2017.

13.

Trans-synaptic homeostasis at the myasthenic neuromuscular junction.

Plomp JJ.

Front Biosci (Landmark Ed). 2017 Mar 1;22:1033-1051. Review.

PMID:
28199191
14.

Optogenetic termination of ventricular arrhythmias in the whole heart: towards biological cardiac rhythm management.

Nyns ECA, Kip A, Bart CI, Plomp JJ, Zeppenfeld K, Schalij MJ, de Vries AAF, Pijnappels DA.

Eur Heart J. 2017 Jul 14;38(27):2132-2136. doi: 10.1093/eurheartj/ehw574.

15.

Continuous infusion of manganese improves contrast and reduces side effects in manganese-enhanced magnetic resonance imaging studies.

Poole DS, Doorenweerd N, Plomp JJ, Mahfouz A, Reinders MJT, van der Weerd L.

Neuroimage. 2017 Feb 15;147:1-9. doi: 10.1016/j.neuroimage.2016.09.030. Epub 2016 Oct 21.

PMID:
27777173
16.

Characterization of neuromuscular synapse function abnormalities in multiple Duchenne muscular dystrophy mouse models.

van der Pijl EM, van Putten M, Niks EH, Verschuuren JJ, Aartsma-Rus A, Plomp JJ.

Eur J Neurosci. 2016 Jun;43(12):1623-35. doi: 10.1111/ejn.13249. Epub 2016 May 9.

PMID:
27037492
17.

The expanding field of IgG4-mediated neurological autoimmune disorders.

Huijbers MG, Querol LA, Niks EH, Plomp JJ, van der Maarel SM, Graus F, Dalmau J, Illa I, Verschuuren JJ.

Eur J Neurol. 2015 Aug;22(8):1151-61. doi: 10.1111/ene.12758. Epub 2015 May 29. Review.

PMID:
26032110
18.

Electrophysiological analysis of neuromuscular synaptic function in myasthenia gravis patients and animal models.

Plomp JJ, Morsch M, Phillips WD, Verschuuren JJ.

Exp Neurol. 2015 Aug;270:41-54. doi: 10.1016/j.expneurol.2015.01.007. Epub 2015 Jan 23. Review.

PMID:
25620417
19.

Tomosyn-2 is required for normal motor performance in mice and sustains neurotransmission at motor endplates.

Geerts CJ, Plomp JJ, Koopmans B, Loos M, van der Pijl EM, van der Valk MA, Verhage M, Groffen AJ.

Brain Struct Funct. 2015 Jul;220(4):1971-82. doi: 10.1007/s00429-014-0766-0. Epub 2014 Apr 18.

PMID:
24744148
20.

The effect of PPE-induced emphysema and chronic LPS-induced pulmonary inflammation on atherosclerosis development in APOE*3-LEIDEN mice.

Khedoe PP, Wong MC, Wagenaar GT, Plomp JJ, van Eck M, Havekes LM, Rensen PC, Hiemstra PS, Berbée JF.

PLoS One. 2013 Nov 26;8(11):e80196. doi: 10.1371/journal.pone.0080196. eCollection 2013.

21.

MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4.

Huijbers MG, Zhang W, Klooster R, Niks EH, Friese MB, Straasheijm KR, Thijssen PE, Vrolijk H, Plomp JJ, Vogels P, Losen M, Van der Maarel SM, Burden SJ, Verschuuren JJ.

Proc Natl Acad Sci U S A. 2013 Dec 17;110(51):20783-8. doi: 10.1073/pnas.1313944110. Epub 2013 Dec 2.

22.

Pathogenic immune mechanisms at the neuromuscular synapse: the role of specific antibody-binding epitopes in myasthenia gravis.

Huijbers MG, Lipka AF, Plomp JJ, Niks EH, van der Maarel SM, Verschuuren JJ.

J Intern Med. 2014 Jan;275(1):12-26. doi: 10.1111/joim.12163. Epub 2013 Nov 29. Review.

23.

The pre-synaptic motor nerve terminal as a site for antibody-mediated neurotoxicity in autoimmune neuropathies and synaptopathies.

Fewou SN, Plomp JJ, Willison HJ.

J Anat. 2014 Jan;224(1):36-44. doi: 10.1111/joa.12088. Epub 2013 Aug 13. Review.

24.

Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4.

Verschuuren JJ, Huijbers MG, Plomp JJ, Niks EH, Molenaar PC, Martinez-Martinez P, Gomez AM, De Baets MH, Losen M.

Autoimmun Rev. 2013 Jul;12(9):918-23. doi: 10.1016/j.autrev.2013.03.001. Epub 2013 Mar 25. Review.

PMID:
23535160
25.

Pathogenic IgG4 subclass autoantibodies in MuSK myasthenia gravis.

Plomp JJ, Huijbers MG, van der Maarel SM, Verschuuren JJ.

Ann N Y Acad Sci. 2012 Dec;1275:114-22. doi: 10.1111/j.1749-6632.2012.06808.x. Review.

PMID:
23278586
26.

Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice.

Klooster R, Plomp JJ, Huijbers MG, Niks EH, Straasheijm KR, Detmers FJ, Hermans PW, Sleijpen K, Verrips A, Losen M, Martinez-Martinez P, De Baets MH, van der Maarel SM, Verschuuren JJ.

Brain. 2012 Apr;135(Pt 4):1081-101. doi: 10.1093/brain/aws025. Epub 2012 Mar 6.

PMID:
22396395
27.

Anti-ganglioside antibody internalization attenuates motor nerve terminal injury in a mouse model of acute motor axonal neuropathy.

Fewou SN, Rupp A, Nickolay LE, Carrick K, Greenshields KN, Pediani J, Plomp JJ, Willison HJ.

J Clin Invest. 2012 Mar;122(3):1037-51. doi: 10.1172/JCI59110. Epub 2012 Feb 6.

28.

Comparison of skeletal muscle pathology and motor function of dystrophin and utrophin deficient mouse strains.

van Putten M, Kumar D, Hulsker M, Hoogaars WM, Plomp JJ, van Opstal A, van Iterson M, Admiraal P, van Ommen GJ, 't Hoen PA, Aartsma-Rus A.

Neuromuscul Disord. 2012 May;22(5):406-17. doi: 10.1016/j.nmd.2011.10.011. Epub 2012 Jan 27.

29.

Severe and progressive neurotransmitter release aberrations in familial hemiplegic migraine type 1 Cacna1a S218L knock-in mice.

Kaja S, Van de Ven RC, Broos LA, Frants RR, Ferrari MD, Van den Maagdenberg AM, Plomp JJ.

J Neurophysiol. 2010 Sep;104(3):1445-55. doi: 10.1152/jn.00012.2010. Epub 2010 Jul 14.

30.

Pre- and postsynaptic neuromuscular junction abnormalities in musk myasthenia.

Niks EH, Kuks JB, Wokke JH, Veldman H, Bakker E, Verschuuren JJ, Plomp JJ.

Muscle Nerve. 2010 Aug;42(2):283-8. doi: 10.1002/mus.21642.

PMID:
20544919
31.

High cortical spreading depression susceptibility and migraine-associated symptoms in Ca(v)2.1 S218L mice.

van den Maagdenberg AM, Pizzorusso T, Kaja S, Terpolilli N, Shapovalova M, Hoebeek FE, Barrett CF, Gherardini L, van de Ven RC, Todorov B, Broos LA, Tottene A, Gao Z, Fodor M, De Zeeuw CI, Frants RR, Plesnila N, Plomp JJ, Pietrobon D, Ferrari MD.

Ann Neurol. 2010 Jan;67(1):85-98. doi: 10.1002/ana.21815.

PMID:
20186955
32.

Total ganglioside ablation at mouse motor nerve terminals alters neurotransmitter release level.

Zitman FM, Todorov B, Furukawa K, Furukawa K, Willison HJ, Plomp JJ.

Synapse. 2010 Apr;64(4):335-8. doi: 10.1002/syn.20747.

PMID:
19957367
33.

Pathophysiological actions of neuropathy-related anti-ganglioside antibodies at the neuromuscular junction.

Plomp JJ, Willison HJ.

J Physiol. 2009 Aug 15;587(Pt 16):3979-99. doi: 10.1113/jphysiol.2009.171702. Epub 2009 Jun 29. Review.

34.

The ataxic Cacna1a-mutant mouse rolling nagoya: an overview of neuromorphological and electrophysiological findings.

Plomp JJ, van den Maagdenberg AM, Kaja S.

Cerebellum. 2009 Sep;8(3):222-30. doi: 10.1007/s12311-009-0117-5. Epub 2009 May 30. Review.

35.

Neuromuscular synaptic transmission in aged ganglioside-deficient mice.

Zitman FM, Todorov B, Verschuuren JJ, Jacobs BC, Furukawa K, Furukawa K, Willison HJ, Plomp JJ.

Neurobiol Aging. 2011 Jan;32(1):157-67. doi: 10.1016/j.neurobiolaging.2009.01.007. Epub 2009 Feb 23.

PMID:
19233512
36.

The neuropathic potential of anti-GM1 autoantibodies is regulated by the local glycolipid environment in mice.

Greenshields KN, Halstead SK, Zitman FM, Rinaldi S, Brennan KM, O'Leary C, Chamberlain LH, Easton A, Roxburgh J, Pediani J, Furukawa K, Furukawa K, Goodyear CS, Plomp JJ, Willison HJ.

J Clin Invest. 2009 Mar;119(3):595-610. doi: 10.1172/JCI37338. Epub 2009 Feb 16.

37.

Loss of transforming growth factor-beta 2 leads to impairment of central synapse function.

Heupel K, Sargsyan V, Plomp JJ, Rickmann M, Varoqueaux F, Zhang W, Krieglstein K.

Neural Dev. 2008 Oct 14;3:25. doi: 10.1186/1749-8104-3-25.

38.

C5 inhibitor rEV576 protects against neural injury in an in vitro mouse model of Miller Fisher syndrome.

Halstead SK, Humphreys PD, Zitman FM, Hamer J, Plomp JJ, Willison HJ.

J Peripher Nerv Syst. 2008 Sep;13(3):228-35. doi: 10.1111/j.1529-8027.2008.00181.x.

PMID:
18844789
39.

Neuromuscular synaptic function in mice lacking major subsets of gangliosides.

Zitman FM, Todorov B, Jacobs BC, Verschuuren JJ, Furukawa K, Furukawa K, Willison HJ, Plomp JJ.

Neuroscience. 2008 Oct 28;156(4):885-97. doi: 10.1016/j.neuroscience.2008.08.034. Epub 2008 Aug 23.

PMID:
18801416
40.

The role of complement and complement regulators in mediating motor nerve terminal injury in murine models of Guillain-Barré syndrome.

Willison HJ, Halstead SK, Beveridge E, Zitman FM, Greenshields KN, Morgan BP, Plomp JJ.

J Neuroimmunol. 2008 Sep 15;201-202:172-82. doi: 10.1016/j.jneuroim.2008.05.028. Epub 2008 Jul 29. Review.

PMID:
18664403
41.

Anti-ganglioside antibodies and the presynaptic motor nerve terminal.

Willison HJ, Plomp JJ.

Ann N Y Acad Sci. 2008;1132:114-23. doi: 10.1196/annals.1405.010. Review.

PMID:
18567860
42.

Reduced ACh release at neuromuscular synapses of heterozygous leaner Ca(v)2.1-mutant mice.

Kaja S, Van De Ven RC, Frants RR, Ferrari MD, Van Den Maagdenberg AM, Plomp JJ.

Synapse. 2008 May;62(5):337-44. doi: 10.1002/syn.20490.

PMID:
18293354
43.

Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model.

Halstead SK, Zitman FM, Humphreys PD, Greenshields K, Verschuuren JJ, Jacobs BC, Rother RP, Plomp JJ, Willison HJ.

Brain. 2008 May;131(Pt 5):1197-208. doi: 10.1093/brain/awm316. Epub 2008 Jan 8.

PMID:
18184663
44.

Genetic models of migraine.

van de Ven RC, Kaja S, Plomp JJ, Frants RR, van den Maagdenberg AM, Ferrari MD.

Arch Neurol. 2007 May;64(5):643-6. Review.

PMID:
17502463
45.

Severely impaired neuromuscular synaptic transmission causes muscle weakness in the Cacna1a-mutant mouse rolling Nagoya.

Kaja S, van de Ven RC, van Dijk JG, Verschuuren JJ, Arahata K, Frants RR, Ferrari MD, van den Maagdenberg AM, Plomp JJ.

Eur J Neurosci. 2007 Apr;25(7):2009-20.

PMID:
17439489
46.

Redundancy of Cav2.1 channel accessory subunits in transmitter release at the mouse neuromuscular junction.

Kaja S, Todorov B, van de Ven RC, Ferrari MD, Frants RR, van den Maagdenberg AM, Plomp JJ.

Brain Res. 2007 Apr 27;1143:92-101. Epub 2007 Jan 26.

PMID:
17320843
47.

Characterization of acetylcholine release and the compensatory contribution of non-Ca(v)2.1 channels at motor nerve terminals of leaner Ca(v)2.1-mutant mice.

Kaja S, van de Ven RC, Broos LA, Frants RR, Ferrari MD, van den Maagdenberg AM, Plomp JJ.

Neuroscience. 2007 Feb 23;144(4):1278-87. Epub 2006 Dec 8.

PMID:
17161543
48.

Conditional inactivation of the Cacna1a gene in transgenic mice.

Todorov B, van de Ven RC, Kaja S, Broos LA, Verbeek SJ, Plomp JJ, Ferrari MD, Frants RR, van den Maagdenberg AM.

Genesis. 2006 Dec;44(12):589-94.

PMID:
17146767
49.

Munc18-1 expression levels control synapse recovery by regulating readily releasable pool size.

Toonen RF, Wierda K, Sons MS, de Wit H, Cornelisse LN, Brussaard A, Plomp JJ, Verhage M.

Proc Natl Acad Sci U S A. 2006 Nov 28;103(48):18332-7. Epub 2006 Nov 16.

50.

Rab3A deletion selectively reduces spontaneous neurotransmitter release at the mouse neuromuscular synapse.

Sons MS, Plomp JJ.

Brain Res. 2006 May 17;1089(1):126-34. Epub 2006 May 2.

PMID:
16631140

Supplemental Content

Loading ...
Support Center